Detailed GuideMHRA
MHRA regulatory flexibilities resulting from coronavirus (COVID-19)
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
First published: Apr 1, 2020Last updated: Aug 4, 2020Changes: 12
Latest change: We have identified areas of flexibility which differ from the EU. These are indicated by an asterisk (*). Please be aware that some UK flexibilities, while aligned with those of the EU, are not limited to treatments for COVID-19 products, but cover the supply of other essential products that have been affected by the outbreak by factors such as travel and transportation restrictions or shortages of starting materials. These are indicated by two asterisks (**).
The full document, source attachments, and change history are available on KeyPedia. Sign in to view.